Technological projects portfolio

The WHO estimates that over 335 million people around the world suffer from persistent allergic asthma, with a high rate of under diagnosis. In France, this represents 6.7% of the population. These numbers are constantly increasing.

Current treatments rely on the systematic use of corticosteroids, which cause harmful side effects if not properly controlled, are not always effective and treat the symptoms without treating the illness.

The ALRIGHT project is based on the identification of a bacteria that colonizes the lungs early in life and  reduces inflammation, the root cause of asthma.

ALRIGHT acts as a supplemental treatment in addition to the standard corticosteroid treatment of respiratory pathologies.

The project specifically targets the treatment of allergic asthma in babies from 0 to 3 years old and in adult patients who do not respond well to corticosteroids.

It can also be used to supplement maintenance treatments for non-allergic asthma.